Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases

BACKGROUND: Radium-223 is a first-in-class targeted alpha therapy to prolong overall survival (OS) in castration-resistant prostate cancer with bone metastases (mCRPC). The aim of the present analysis was to assess the long-term safety with radium-223 in Japanese patients with mCRPC. METHODS: Patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Uemura, Hirotsugu, Uemura, Hiroji, Nagamori, Satsohi, Wakumoto, Yoshiaki, Kimura, Go, Kikukawa, Hiroaki, Yokomizo, Akira, Mizokami, Atsushi, Kosaka, Takeo, Masumori, Naoya, Kawasaki, Yoshihide, Yonese, Junji, Nasu, Yasutomo, Fukasawa, Satoshi, Sugiyama, Takayuki, Kinuya, Seigo, Hosono, Makoto, Yamaguchi, Iku, Akagawa, Takashi, Matsubara, Nobuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469691/
https://www.ncbi.nlm.nih.gov/pubmed/30875000
http://dx.doi.org/10.1007/s10147-018-01389-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469691/
https://www.ncbi.nlm.nih.gov/pubmed/30875000
http://dx.doi.org/10.1007/s10147-018-01389-4

Ejemplares similares